At a Glance
- Company: Servier acquiring Day One Biopharmaceuticals
- Location: Servier (France); Day One (Brisbane, California)
- Deal value: About 2.5 billion USD in cash (21.50 USD per share)
- Focus area: Paediatric low‑grade glioma (pLGG) and rare cancers
- Next steps: Close pending approvals; integrate Ojemda and pipeline
What happened?
Servier has agreed to acquire Day One Biopharmaceuticals in an all‑cash transaction valued at roughly 2.5 billion USD, paying 21.50 USD per share. The deal hands Servier full ownership of Ojemda, Day One’s recently approved targeted therapy for paediatric low‑grade glioma, along with a small pipeline of MAPK‑pathway–focused oncology assets. The companies expect the transaction to close after customary regulatory and shareholder approvals.
Why does it matter?
Paediatric low‑grade glioma is the most common childhood brain tumour, but until very recently there were limited targeted options and many children relied on toxic chemotherapies or repeated surgery and radiation. By acquiring Ojemda, Servier consolidates a first‑in‑class, biomarker‑driven therapy in a rare paediatric population, strengthening its positioning in niche, high‑unmet‑need oncology. The deal also underscores continuing big‑pharma appetite for de‑risked, recently approved oncology assets, even in a cautious M&A environment.
Who’s behind it?
Servier is a privately held French pharma group with a growing oncology franchise, including drugs in colorectal cancer and other solid tumours. Day One Biopharmaceuticals is a US‑based biotech built around the concept of bringing targeted therapies to children “on day one” of drug development rather than as an afterthought. With this acquisition, Day One’s commercial and development operations will be folded into Servier’s global oncology organisation.
How was it achieved?
The transaction is structured as an all‑cash tender at 21.50 USD per share, representing a premium to Day One’s recent trading price and valuing the company at about 2.5 billion USD on a fully diluted basis. Strategically, Servier gains a commercial‑stage product with an existing launch footprint in paediatric neuro‑oncology, plus development opportunities in related MAPK‑driven tumours. Day One’s expertise in paediatric trial design and relationships with children’s cancer centres also complement Servier’s broader oncology network.
What’s next?
Following closing, Servier is expected to continue and potentially broaden Ojemda’s rollout in key markets, including expanding access through additional regulatory submissions outside the US. Development‑wise, Servier is likely to pursue label expansions into other BRAF‑ or MAPK‑altered paediatric and possibly adult brain tumours, while evaluating how Day One’s earlier‑stage programmes fit within its oncology pipeline. For Day One shareholders, the transaction provides an immediate cash exit and marks a relatively swift transition from first approval to acquisition.